You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
濟民健康(603222.SH):公司會積極利用國家給予博鰲樂城國際醫療旅遊先行區的相關產業優惠政策
格隆匯 09-25 15:41

格隆匯9月25日丨濟民健康(603222.SH)在互動平台表示,博鰲國際醫院是一家以生物醫學新技術發展研究、細胞存儲及服務為特色的研究型醫院。醫院位於海南博鰲樂城國際醫療旅遊先行區,總用地面積約81.2畝,總建築面積6.5萬平方米,核定病牀數560張,於2018年開業運營,經過多年的培育與發展,2023年扭虧為盈,當年實現淨利潤3,325.50萬元。 生物醫學新技術是公司未來研發投入的重點,代表着公司未來的發展方向,而其載體為博鰲國際醫院。醫院目前處於臨牀前研究階段的細胞治療藥物管線包括 ADSC治療視網膜色素變性、ADSC 治療II型糖尿病、 ADSC 治療慢性阻塞性肺疾病、cDC1 治療前列腺癌、cDC1 治療肝癌、cDC1 治療肺癌以及 INKT 用於泛癌種術後輔助治療。公司會積極利用國家給予博鰲樂城國際醫療旅遊先行區的相關產業優惠政策,通過與國際頂尖的專家團隊合作,引進國際前沿醫藥科技成果,提升醫院整體醫療技術服務水平及基礎研究和臨牀科研實力,致力於將醫院打造成為國內技術領先、國際上最具特色的現代醫學研究與治療基地。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account